Altay Biopharma
About us
The Science
Pipeline
Team
Contact
Careers
News
About us





Altay Therapeutics discovers novel small molecule drugs targeting disease-causing transcription factors






Robust Platform and screening approach:
Our novel approach enables the identification of new small molecule binding sites within previously "undruggable" transcription factors. Using a combination of genetics and molecular simulations, we developed a robust approach to find new small molecule binding pockets. Using this approach, we developed potent small molecules with exceptional drug-like properties for a number of diseases that include facioscapulohumeral muscular dystrophy (FSHD), idiopathic pulmonary fibrosis (IPF), Ewing's Sarcoma and prostate cancer.

The Science


Altay develops small molecule drugs that inhibit disease-causing transcription factors (TFs). Our platform, enables us to identify inhibitors against TF's across many therapeutic areas. Our mechanism of inhibition enables us to drug  "undruggable" proteins giving us a significant leading advantage over our competitors.


Pipeline


Our pre-clinical studies with our current lead candidate for the treatment of Ewing's Sarcoma and prostate cancer show great in vivo efficacy and specificity to ETS-driven cancers with no toxicity in non-ETS driven cells. 


Our pre-clinical studies with our current lead for the treatment of IPF show great in vivo efficacy where we demonstrate both prevention and reversal of collagen deposition in the lung.


Using our platform technology, we have identified the first-in-class inhibitor targeting DUX4. Efforts are underway in testing their efficacy in several in vitro and in vivo assays.


Team

Founders


Ali Rayet Ozes. PhD.

Founder and CEO

  * Lead scientist. Mechanism of small molecules for oncology program - Nalo Therapeutics

  * Post-doctoral Researcher - Janssen Biopharma

  * University of California, Davis (B.S.)

  * Indiana University, Bloomington (PhD.) Biochemistry and Molecular Biology.


Osman Nidai Ozes. PhD.

Founder and CSO

  * Professor of Genetics. Mechanism of inflammatory response in cancer - Akdeniz University

  * Director of Research. Lead of Esbriet IPF program- Intermune Inc.

  * Haccettepe University, Ankara (B.S and M.S.)

  * Indiana University, Bloomiongton (PhD) Immunology




Scientific Advisors


Lee Latimer. PhD.

Medicinal Chemistry-Consultant

* Board of Directors, director-at-large - American Chemical Society (2016-2018)

* Senior Director, Process and Analytical Chemistry - Elan Inc. (1995-2011)

* University of Wisconsin (PhD.)



Kamran Atabai. MD.

Fibrosis Expert

* Associate Professor of Medicine - University of California San Francisco

* Fellowship - Pulmonary and Critical care - Harvard

* Residency - School of Medicine - University of California San Francisco

Paul Wolters. MD.

Fibrosis Expert

* Professor - University of California San Francisco

* Director - UCSF Interstitial Lung Disease Program

* Residency - University of Colorado

Aykut Uren. MD.

Ewing's Sarcoma Expert

* Professor - Georgetown University

* Assistant Director, Genomics and Epigenomics Shared Resource Advisory Committee

* Residency - Hacettepe University, Ankara



Contact

Altay is located at the Bayer Colaborator in San Francisco Mission Bay.

For more information please contact us:

info@altaytherapeutics.com

Address:

455 Mission Bay

Boulevard South

San Francisco, CA 94158

Careers

Please check back soon for upcoming opportunities to work with us!

News

FSHD Global invests in Altay!

September 2021

We are delighted to share that FSHD Global has invested in Altay to further development of our anti-DUX4 program. Upregulated expression of DUX4 leads to muscle cell death in patients suffering from facioscapulohumeral muscular dystrophy (FSHD). Successful inhibition of DUX4 with small molecules will prevent muscle death leading to a better quality of life. We are honored to be in this fight with the friends of FSHD.

Altay is awarded grant from Friends of FSHD!

May 2021

We are delighted to share that Altay Therapeutics Inc. was awarded a grant from the Friends of FSH foundation to implement our platform for the discovery of small molecule inhibitors targeting transcription factor, DUX4. Upregulated expression of DUX4 leads to muscle cell death in patients suffering from facioscapulohumeral muscular dystrophy (FSHD). Successful inhibition of DUX4 with small molecules will prevent muscle death leading to a better quality of life. We are honored to be in this fight with the friends of FSHD.

Altay is accepted into Y-Combinator's Winter 2020 class!

January 2020

We are delighted to share with you that Altay Therapeutics Inc. was accepted into Y-combinator's Winter 2020 program to develop our platform technology and our fibrosis program!

Altay is now part of Bayer Collaborator!

December 2020

We are excited to announce that Altay's Therapeutics Inc. new home will be at Bayer Collaborator in San Francisco Mission Bay!